vs
Side-by-side financial comparison of Bolt Biotherapeutics, Inc. (BOLT) and Cycurion, Inc. (CYCU). Click either name above to swap in a different company.
Cycurion, Inc. is the larger business by last-quarter revenue ($3.5M vs $2.5M, roughly 1.4× Bolt Biotherapeutics, Inc.). Cycurion, Inc. runs the higher net margin — -141.2% vs -265.2%, a 124.0% gap on every dollar of revenue. Over the past eight quarters, Cycurion, Inc.'s revenue compounded faster (-8.6% CAGR vs -31.2%).
Bolt Biotherapeutics, Inc. is a clinical-stage biotechnology company specializing in immune-stimulating antibody conjugate (ISAC) therapies for cancer treatment. Its core pipeline targets hard-to-treat solid tumors, serving global oncology markets and advancing novel immunotherapies that trigger targeted anti-tumor immune responses to improve patient outcomes.
BOLT vs CYCU — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $2.5M | $3.5M |
| Net Profit | $-6.6M | $-5.0M |
| Gross Margin | — | 12.1% |
| Operating Margin | -283.4% | -141.7% |
| Net Margin | -265.2% | -141.2% |
| Revenue YoY | — | -13.1% |
| Net Profit YoY | 58.4% | -546.8% |
| EPS (diluted) | $-9.38 | $-11.09 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $2.5M | $3.5M | ||
| Q3 25 | $2.2M | $3.8M | ||
| Q2 25 | $1.8M | $3.9M | ||
| Q1 25 | $1.2M | $3.9M | ||
| Q4 24 | $0 | $4.1M | ||
| Q3 24 | $1.1M | $4.5M | ||
| Q2 24 | $1.3M | $5.0M | ||
| Q1 24 | $5.3M | $4.2M |
| Q4 25 | $-6.6M | $-5.0M | ||
| Q3 25 | $-7.1M | $-3.1M | ||
| Q2 25 | $-8.6M | $-5.3M | ||
| Q1 25 | $-11.0M | $-10.2M | ||
| Q4 24 | $-15.9M | $1.1M | ||
| Q3 24 | $-15.2M | $116.1K | ||
| Q2 24 | $-21.2M | $306.1K | ||
| Q1 24 | $-10.8M | $-312.5K |
| Q4 25 | — | 12.1% | ||
| Q3 25 | — | 7.1% | ||
| Q2 25 | — | 6.1% | ||
| Q1 25 | — | 17.5% | ||
| Q4 24 | — | 37.9% | ||
| Q3 24 | — | 16.1% | ||
| Q2 24 | — | 20.5% | ||
| Q1 24 | — | 8.2% |
| Q4 25 | -283.4% | -141.7% | ||
| Q3 25 | -355.1% | -118.2% | ||
| Q2 25 | -510.5% | -96.9% | ||
| Q1 25 | -991.4% | -260.9% | ||
| Q4 24 | — | 31.9% | ||
| Q3 24 | -1441.1% | 9.4% | ||
| Q2 24 | -1772.3% | 14.6% | ||
| Q1 24 | -324.1% | -0.8% |
| Q4 25 | -265.2% | -141.2% | ||
| Q3 25 | -329.4% | -81.5% | ||
| Q2 25 | -474.6% | -136.1% | ||
| Q1 25 | -903.4% | -264.8% | ||
| Q4 24 | — | 27.5% | ||
| Q3 24 | -1330.1% | 2.6% | ||
| Q2 24 | -1662.4% | 6.1% | ||
| Q1 24 | -205.0% | -7.4% |
| Q4 25 | $-9.38 | $-11.09 | ||
| Q3 25 | $-3.72 | $-1.59 | ||
| Q2 25 | $-4.46 | $-0.15 | ||
| Q1 25 | $-0.29 | $-0.56 | ||
| Q4 24 | $-13.73 | $1.56 | ||
| Q3 24 | $-7.93 | $0.11 | ||
| Q2 24 | $-11.12 | $0.01 | ||
| Q1 24 | $-0.28 | $-0.02 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $27.5M | $5.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $26.5M | $20.1M |
| Total Assets | $56.7M | $33.5M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $27.5M | $5.3M | ||
| Q3 25 | $31.9M | $3.7M | ||
| Q2 25 | $34.8M | $1.0M | ||
| Q1 25 | $38.8M | — | ||
| Q4 24 | $47.3M | $38.7K | ||
| Q3 24 | $53.8M | — | ||
| Q2 24 | $73.7M | — | ||
| Q1 24 | $91.3M | — |
| Q4 25 | $26.5M | $20.1M | ||
| Q3 25 | $32.1M | $19.1M | ||
| Q2 25 | $38.8M | $14.0M | ||
| Q1 25 | $46.8M | $12.9M | ||
| Q4 24 | $57.2M | $3.5M | ||
| Q3 24 | $72.0M | $-3.7M | ||
| Q2 24 | $85.9M | $-3.4M | ||
| Q1 24 | $104.2M | $-2.8M |
| Q4 25 | $56.7M | $33.5M | ||
| Q3 25 | $65.1M | $32.3M | ||
| Q2 25 | $75.5M | $30.7M | ||
| Q1 25 | $85.9M | $31.5M | ||
| Q4 24 | $99.6M | $25.6M | ||
| Q3 24 | $109.3M | $2.9M | ||
| Q2 24 | $124.2M | $2.7M | ||
| Q1 24 | $142.9M | $3.1M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-7.2M | $-3.3M |
| Free Cash FlowOCF − Capex | — | $-3.5M |
| FCF MarginFCF / Revenue | — | -98.8% |
| Capex IntensityCapex / Revenue | — | 5.3% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | $-12.5M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-7.2M | $-3.3M | ||
| Q3 25 | $-9.7M | $-2.5M | ||
| Q2 25 | $-9.6M | $-3.6M | ||
| Q1 25 | $-13.4M | $-2.7M | ||
| Q4 24 | $-14.4M | $-205.7K | ||
| Q3 24 | $-14.0M | $-315.2K | ||
| Q2 24 | $-16.1M | $-578.0K | ||
| Q1 24 | $-16.8M | $-272.4K |
| Q4 25 | — | $-3.5M | ||
| Q3 25 | — | $-2.6M | ||
| Q2 25 | — | $-3.7M | ||
| Q1 25 | — | $-2.8M | ||
| Q4 24 | — | $-310.7K | ||
| Q3 24 | $-14.0M | $-420.2K | ||
| Q2 24 | — | $-711.0K | ||
| Q1 24 | — | $-377.4K |
| Q4 25 | — | -98.8% | ||
| Q3 25 | — | -66.9% | ||
| Q2 25 | — | -94.2% | ||
| Q1 25 | — | -72.7% | ||
| Q4 24 | — | -7.6% | ||
| Q3 24 | -1227.6% | -9.4% | ||
| Q2 24 | — | -14.2% | ||
| Q1 24 | — | -8.9% |
| Q4 25 | — | 5.3% | ||
| Q3 25 | — | 2.5% | ||
| Q2 25 | — | 2.7% | ||
| Q1 25 | — | 1.8% | ||
| Q4 24 | — | 2.6% | ||
| Q3 24 | 3.6% | 2.4% | ||
| Q2 24 | 0.0% | 2.7% | ||
| Q1 24 | 0.0% | 2.5% |
| Q4 25 | — | — | ||
| Q3 25 | — | — | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | -0.18× | ||
| Q3 24 | — | -2.71× | ||
| Q2 24 | — | -1.89× | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
